Vidofludimus calcium - Immunic

Drug Profile

Vidofludimus calcium - Immunic

Alternative Names: IM 90838; IMU 838

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 4SC
  • Developer Immunic
  • Class Antiulcers; Cyclopentanes; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Phase I Crohn's disease

Most Recent Events

  • 15 Mar 2018 Phase-II clinical trials in Ulcerative colitis (Treatment-experienced, In adults, In the elderly) in USA (PO) (NCT03341962)
  • 17 Jan 2018 Immunic AG plans the phase II CALDOSE-1 trial for Ulcerative colitis (Treatment-experienced, In adults, In the elderly) in Germany in early 2018 (PO) (NCT03341962)
  • 16 Jan 2018 USFDA approves IND application for IM 838 in Ulcerative colitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top